The Semaglutide EVOKE Plus trial (NCT04777409) is a Phase 3 equivalent clinical trial evaluating the efficacy and safety of oral semaglutide (14 mg once daily) in patients with early Alzheimer's disease. Sponsored by Novo Nordisk, this trial represents one of the largest ongoing AD therapeutic studies, enrolling approximately 1,840 participants across multiple international sites[1][2].
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for Type 2 diabetes and obesity. This trial tests the hypothesis that GLP-1 receptor activation can exert neuroprotective effects in Alzheimer's disease through multiple mechanisms, including reduced neuroinflammation, improved insulin signaling, and enhanced mitochondrial function[3][4].
Trial Identifier: NCT04777409
Status: Active, not recruiting (as of March 2026)
Start Date: 2021
Estimated Completion: 2025-2026
Phase: Phase 3
Enrollment: 1,840 participants
Sponsor: Novo Nordisk A/S
Alzheimer's disease is increasingly recognized as a disorder with significant metabolic components. Type 2 diabetes mellitus is a established risk factor for AD, and insulin resistance is commonly observed in the brains of AD patients. This has led to the "type 3 diabetes" hypothesis, which proposes that AD represents a form of brain-specific insulin resistance[5].
GLP-1 receptor agonists like semaglutide address multiple aspects of this metabolic dysfunction:
GLP-1 receptors are expressed in multiple brain regions relevant to Alzheimer's disease, including the hippocampus (critical for memory), cortex, and basal forebrain. Activation of these receptors triggers intracellular signaling cascades that exert neuroprotective effects[3:1][4:1]:
The Evidence for Liraglutide in Alzheimer's Disease (ELAD) trial was a landmark study evaluating liraglutide (another GLP-1 agonist) in patients with mild AD[6]:
Key Findings:
Multiple preclinical studies have demonstrated semaglutide's neuroprotective properties:
Design: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 trial
Allocation: 1:1 randomization to semaglutide vs. placebo
Duration: 104 weeks (2 years) of treatment
| Arm | Intervention | Dosage |
|---|---|---|
| Semaglutide | Oral semaglutide | 14 mg once daily |
| Placebo | Oral placebo | Once daily |
Cognitive Endpoint:
Functional Endpoint:
Cognitive Measures:
Biomarker Measures:
Safety Measures:
The EVOKE Plus trial is conducted at over 200 sites across North America, Europe, Asia, and Australia. Sites include major academic medical centers and specialized memory clinics.
The Semaglutide EVOKE Plus trial represents a critical test of the metabolic/inflammatory hypothesis of Alzheimer's disease. If positive, it could:
The trial results are expected in 2025-2026 and will be pivotal for the field of metabolic therapies in neurodegeneration.
ClinicalTrials.gov. Semaglutide (EVOKE Plus) - NCT04777409. 2026. ↩︎
Novo Nordisk. Semaglutide EVOKE Plus Phase 3 Program in Alzheimer's Disease. ↩︎
Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and disease-modifying effects of the triple GLP-1/GIP/glucagon receptor agonist DA-CH3 in an Alzheimer's disease model. J Pharmacol Exp Ther. 2022. ↩︎ ↩︎
Zhang L, Zhang L, Li L, et al. Neuroprotective effects of GLP-1 receptor agonist on cognitive deficits and mitochondrial dysfunction in a mouse model of Alzheimer's disease. Neurochem Res. 2020. ↩︎ ↩︎
de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008. ↩︎
Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer's disease, 6-month treatment with GLP-1 analog liraglutide reduces brain glucose metabolism while preserving cognition. Front Aging Neurosci. 2016. ↩︎
Bomba M, Granzotto A, Castelli V, et al. GLP-1 receptor agonist exenatide protects against synaptic plasticity impairment in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2018. ↩︎
Pan X, Gong N, Zhao J, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain. 2010. ↩︎
Liu W, Jalewa I, Sharma M, et al. Neuroprotective effects of GLP-1 analog liraglutide in the 5xFAD mouse model of Alzheimer's disease. J Alzheimers Dis. 2015. ↩︎
McClean PL, Hölscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load and inflammation in a mouse model of Alzheimer's disease. Neuropharmacology. 2014. ↩︎